Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
1,139
Recruiting, any sponsor type, condition "small cell lung cancer"
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting1,139
- Completed2,854
1,139 trials
Showing 1 to 25, recently updated first.
PfizerPfizer (PFE)
NCT07476287 · 40 participants (planned) · Start Jul 2, 2026 · Primary completion Mar 24, 2028
Drug: PF-08634404; Chemotherapy · For: Small Cell Lung Cancer; Small Cell Lung Cancer ( SCLC ); Transformed Small Cell Lung Cancer and 3 more
Sites: Duarte, California; Encinitas, California; Irvine, California · 75 sites in all
- Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC TrialPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT07388524 · 336 participants (planned) · Start Mar 2, 2027 · Primary completion Sep 30, 2032
Drug: Atezolizumab; Atezolizumab and Recombinant Human Hyaluronidase · For: Lung Non-Small Cell Carcinoma
Sites: Anaheim, California; Baldwin Park, California; Bellflower, California · 171 sites in all
- Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT TrialPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT06498635 · 306 participants (planned) · Start Apr 1, 2025 · Primary completion Jul 15, 2039
Drug: Durvalumab · For: Lung Non-Small Cell Carcinoma; Stage II Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8 and 1 more
Sites: Jonesboro, Arkansas; Beverly Hills, California; Dublin, California · 287 sites in all
PfizerPfizer (PFE)
NCT07227298 · 162 participants (planned) · Start Jan 30, 2026 · Primary completion Mar 8, 2029
Drug: PF-08634404; Sigvotatug Vedotin and 1 more · For: Advanced/Metastatic Non-Small Cell Lung Cancer; Carcinoma, Non-Small Cell Lung; Non-Small Cell Lung Cancer
Sites: Fayetteville, Arkansas; Rogers, Arkansas; Springdale, Arkansas · 108 sites in all
National Cancer Institute (NCI)NIH
NCT02133196 · 85 participants (planned) · Start Oct 23, 2014 · Primary completion Oct 23, 2027
Drug: Aldesleukin; Fludarabine and 2 more · For: Advanced Non-Small Cell Lung Cancer; Squamous Cell Carcinoma; Advanced NSCLC and 2 more
Sites: Bethesda, Maryland
- A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)Recruiting
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT07140016 · 40 participants (planned) · Start Sep 22, 2025 · Primary completion Dec 31, 2029
Drug: gilteritinib · For: Non-small Cell Lung Cancer (NSCLC); Anaplastic Lymphoma Kinase (ALK) Positive
Sites: Fullerton, California; Orange, California; Edwards, Colorado · 17 sites in all
Molecular Partners AGIndustry
NCT07278479 · 138 participants (planned) · Start May 18, 2026 · Primary completion Sep 2028
Drug: [212Pb]Pb-MP0712 · For: Large Cell Neuroendocrine Carcinoma; Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC); Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) and 4 more
Sites: Miami, Florida; Tampa, Florida; Atlanta, Georgia · 9 sites in all
Whitehawk Therapeutics, Inc.Industry
NCT07444814 · 226 participants (planned) · Start Dec 19, 2025 · Primary completion Sep 2028
Drug: HWK-007 · For: Endometrial Cancer; Ovarian Cancer; Ovarian Cancer Metastatic and 4 more
Sites: Birmingham, Alabama; Tucson, Arizona; Little Rock, Arkansas · 17 sites in all
IDEAYA BiosciencesIndustry
NCT07277413 · 570 participants (planned) · Start Mar 4, 2026 · Primary completion Apr 30, 2028
Drug: IDE892; IDE397 and 1 more · For: Bladder Cancer; Mesothelioma; Pleural Mesothelioma and 5 more
Sites: Goodyear, Arizona; Phoenix, Arizona; Duarte, California · 26 sites in all
- DESTINY-PANTUMOUR04Recruiting
AstraZenecaAstraZeneca (AZN)
NCT07124000 · 100 participants (planned) · Start Sep 18, 2025 · Primary completion Mar 30, 2028
Drug: Trastuzumab deruxtecan · For: Adenocarcinoma (NOS); Anal Cancer; Bladder Cancer and 24 more
Sites: Birmingham, Alabama; Bullhead City, Arizona; Casa Grande, Arizona · 18 sites in all
PfizerPfizer (PFE)
NCT07489066 · 120 participants (planned) · Start Jun 30, 2026 · Primary completion Jul 29, 2028
Drug: PF-08634404; Chemotherapy Regimen 1 and 1 more · For: Carcinoma; Non-Small-Cell Lung; Lung Cancer (NSCLC) and 6 more
Sites: Huntsville, Alabama; Stanford, California; Athens, Georgia · 66 sites in all
- Phase 1 Study of OP-3136 in Advanced or Metastatic Solid TumorsPivotal-lookingRecruiting
Olema Oncology, Inc.Industry
NCT06784193 · 180 participants (planned) · Start Dec 16, 2024 · Primary completion May 30, 2027
Drug: OP-3136; Fulvestrant and 1 more · For: Advanced or Metastatic ER+ HER2- Breast Cancer (mBC); Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC); Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC) and 3 more
Sites: Gilbert, Arizona; Aurora, Colorado; Sarasota, Florida · 25 sites in all
- Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07222566 · 1,410 participants (planned) · Start Jan 6, 2026 · Primary completion Feb 27, 2029
Drug: PF-08634404; Pembrolizumab and 2 more · For: Advanced Non-Small Cell Lung Cancer; Non-Small Cell Lung Cancer; Carcinoma, Non-Small-Cell Lung and 3 more
Sites: Bullhead City, Arizona; Chandler, Arizona; Gilbert, Arizona · 560 sites in all
National Cancer Institute (NCI)NIH
NCT03191149 · 46 participants (planned) · Start Apr 25, 2018 · Primary completion Jun 30, 2027
Drug: Osimertinib · For: Advanced Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage IIIB Lung Non-Small Cell Cancer AJCC v7 and 1 more
Sites: Anchorage, Alaska; Fairbanks, Alaska; Fort Smith, Arkansas · 347 sites in all
Kestrel Therapeutics, Inc.Academic, hospital or other
NCT07458347 · 545 participants (planned) · Start Apr 21, 2026 · Primary completion Apr 2028
Drug: KST-6051; Gemcitabine/nab-paclitaxel and 6 more · For: KRAS-mutant Non-small Cell Lung Cancer (NSCLC); KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC); KRAS-mutant Colorectal Cancer (CRC) and 1 more
Sites: Los Angeles, California; Sarasota, Florida; Tampa, Florida · 9 sites in all
Haihua YuanAcademic, hospital or other
NCT07631884 · 15 participants (planned) · Start May 12, 2026 · Primary completion Dec 31, 2028
Drug: Trastuzumab Rezetecan · For: Solid Tumors; Neoplasms (Cancer / Tumors); Advanced Malignant Solid Neoplasm and 13 more
Sites: Shanghai, China
Voronoi, IncIndustry
NCT07699328 · 315 participants (planned) · Start Mar 26, 2024 · Primary completion Jan 1, 2029
Drug: VRN110755 · For: EGFR-Mutant Non-Small Cell Lung Cancer
Sites: Bedford Park, Australia; Clayton, Australia; Toronto, Canada · 29 sites in all
National Cancer Institute (NCI)NIH
NCT06406465 · 60 participants (planned) · Start Nov 25, 2026 · Primary completion Jul 30, 2027
Drug: Belinostat; Cisplatin and 1 more · For: Carcinoma, Neuroendocrine; Tumor, Neuroendocrine; Tumors, Neuroendocrine and 2 more
Sites: Bethesda, Maryland
Wayshine Biopharm, Inc.Industry
NCT06868485 · 40 participants (planned) · Start Aug 18, 2025 · Primary completion Sep 30, 2027
Drug: WSD0922-FU Tablets, Dose level A; WSD0922-FU Tablets, Dose level B · For: Non Small Cell Lung Cancer
Sites: Weston, Florida; Manahawkin, New Jersey; Teaneck, New Jersey · 16 sites in all
- A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung CancerPivotal-lookingRecruiting
Verastem, Inc.Industry
NCT07659782 · 105 participants (planned) · Start Jul 22, 2026 · Primary completion Jun 2027
Drug: VS-7375 · For: Non-Small Cell Lung Cancer
Sites: Scottsdale, Arizona; Los Angeles, California; Aurora, Colorado · 27 sites in all
- A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D MutationPivotal-lookingRecruiting
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT07566052 · 356 participants (planned) · Start Aug 19, 2026 · Primary completion Jun 30, 2030
Drug: Setidegrasib; Docetaxel · For: Non-small Cell Lung Cancer (NSCLC)
Sites: Glendale, California; Los Angeles, California; San Francisco, California · 38 sites in all
National Cancer Institute (NCI)NIH
NCT06066138 · 30 participants (planned) · Start Nov 4, 2025 · Primary completion Jan 31, 2027
Drug: Atezolizumab · For: Locally Advanced Alveolar Soft Part Sarcoma; Metastatic Alveolar Soft Part Sarcoma; Locally Advanced Non Small Cell Lung Cancer and 7 more
Sites: Bethesda, Maryland
- Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung CancerPivotal-lookingRecruiting
Second Xiangya Hospital of Central South UniversityAcademic, hospital or other
NCT05979818 · 118 participants (planned) · Start Nov 13, 2024 · Primary completion Oct 31, 2028
Drug: Propranolol hydrochloride; Sintilimab and 3 more · For: Non Small Cell Lung Cancer; Propranolol; Immune Checkpoint Inhibitors and 4 more
Sites: Changsha, China · 4 sites in all
- 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer DetectionRecruiting
National Cancer Institute (NCI)NIH
NCT06503146 · 320 participants (planned) · Start Sep 9, 2025 · Primary completion Jun 1, 2028
Drug: [18F]FAPI-74; [18F]FDG · For: Sarcoma; Small Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC); Mesothelioma and 7 more
Sites: Bethesda, Maryland
VA Office of Research and DevelopmentFederal agency
NCT05467748 · 66 participants (planned) · Start Dec 8, 2025 · Primary completion Dec 8, 2027
Drug: Tulmimetostat · For: Non Small Cell Lung Cancer
Sites: Long Beach, California; Sacramento, California; San Diego, California · 5 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.